A new patent covering tumor suppression technologies, including the company’s lead product candidate Oncoprex™, was recently awarded to The University of Texas System by the Japan Patent Office.
Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today that its first product candidate, the nanomolecular cancer therapy CNVN202, will be branded as Oncoprex™.
Composition of Matter Patent Covers Broad Therapeutic and Diagnostic Applications
AUSTIN, TX, June 28, 2011 – Genprex, Inc. announced today that a United States Patent has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services. U.S. Patent No. 7,902,441 is one of 23 patents
Oncoprex™ Phase I clinical trial data presented at the 2011 Annual Meeting of the American Association for Cancer Research in Orlando, Florida. Dr Charles Lu of MD Anderson Cancer Center presented the award winning abstract and poster describing the phase I
SPORE Grants Turn Into Hope for Patients